Clinical Trial Update: A Study to Test Whether Different Doses of Alteplase Help People With Severe Breathing Problems Because of COVID-19 [Phase 2, Phase 3]

View source ↗

Summary

A study evaluating different doses of alteplase for severe respiratory problems due to COVID-19 has completed phases 2 and 3, with results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• Alteplase (alteplase)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Acute Respiratory Distress Syndrome | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2024-03-07